Does RUXOLITINIB Cause Therapy non-responder? 274 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 274 reports of Therapy non-responder have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.4% of all adverse event reports for RUXOLITINIB.
274
Reports of Therapy non-responder with RUXOLITINIB
0.4%
of all RUXOLITINIB reports
82
Deaths
44
Hospitalizations
How Dangerous Is Therapy non-responder From RUXOLITINIB?
Of the 274 reports, 82 (29.9%) resulted in death, 44 (16.1%) required hospitalization, and 18 (6.6%) were considered life-threatening.
Is Therapy non-responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 274 reports have been filed with the FAERS database.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Therapy non-responder?
ETANERCEPT (3,472)
APREMILAST (3,360)
METHOTREXATE (2,965)
RITUXIMAB (2,731)
ADALIMUMAB (2,595)
PREDNISONE (2,563)
TREPROSTINIL (2,289)
INFLIXIMAB (2,122)
TOCILIZUMAB (1,775)
HYDROXYCHLOROQUINE (1,699)
Which RUXOLITINIB Alternatives Have Lower Therapy non-responder Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE